NASDAQ:RGNX

Regenxbio Stock Insider Trading

Healthcare > Biotechnology

Buy RGNX

*Your capital is at risk

$12.75

-1.20 (-8.60%)

At Close: Jul 13, 2026

REGENXBIO Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 4.71. In total, the insiders bought 2.72M and sold 466.71K RGNX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	4.71
● Buy	2.72M shares
● Sell	466.71K shares
73% Buy Activity Moderate Negative Correlation
Sell Signal Low Confidence Jul 01, 2026 Analysis Breakdown: Weakened by a contradictory positive Insider Power Score. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 02, 2026 Buy	Stock Options (Right to Buy) M-Exempt	Pakola Steve Chief Medical Officer	Officer	2 161 Value: $17.0K
Jul 02, 2026 Buy	Common Stock M-Exempt	Pakola Steve Chief Medical Officer	Officer	2 161 Value: $17.0K
Jul 02, 2026 Sell	Common Stock S-Sale	Pakola Steve Chief Medical Officer	Officer	2 161 Value: $29.5K
Jul 01, 2026 Sell	Common Stock F-InKind	Simpson Curran Chief Executive Officer	CEO / President	6 818 Value: $89.2K
Jul 01, 2026 Buy	Stock Options (Right to Buy) M-Exempt	Pakola Steve Chief Medical Officer	Officer	36 725 Value: $288.7K
Jul 01, 2026 Buy	Common Stock M-Exempt	Pakola Steve Chief Medical Officer	Officer	36 725 Value: $288.7K
Jul 01, 2026 Sell	Common Stock S-Sale	Pakola Steve Chief Medical Officer	Officer	36 725 Value: $472.3K
Jun 30, 2026 Buy	Common Stock A-Award	Simpson Curran Chief Executive Officer	CEO / President	1 453 Value: $14.8K
Jun 29, 2026 Sell	Common Stock S-Sale	Pakola Steve Chief Medical Officer	Officer	19 608 Value: $216.5K
May 29, 2026 Buy	Common Stock A-Award	Bennett Jean Director	Director	9 807 Value: $68.7K
May 29, 2026 Buy	Stock Options (Right to Buy) A-Award	Bennett Jean Director	Director	46 600 Value: $326.7K
May 29, 2026 Buy	Common Stock A-Award	Glucksmann Alexandra Director	Director	9 807 Value: $68.7K
May 29, 2026 Buy	Stock Options (Right to Buy) A-Award	Glucksmann Alexandra Director	Director	46 600 Value: $326.7K
May 29, 2026 Buy	Common Stock A-Award	Karabelas Argeris N Director	Director	9 807 Value: $68.7K
May 29, 2026 Buy	Stock Options (Right to Buy) A-Award	Karabelas Argeris N Director	Director	46 600 Value: $326.7K
May 29, 2026 Buy	Common Stock A-Award	Migausky George V Director	Director	9 807 Value: $68.7K
May 29, 2026 Buy	Stock Options (Right to Buy) A-Award	Migausky George V Director	Director	46 600 Value: $326.7K
May 29, 2026 Buy	Stock Options (Right to Buy) A-Award	Mills Kenneth T. Director	Director	46 600 Value: $326.7K
May 29, 2026 Buy	Stock Options (Right to Buy) A-Award	Tasse Daniel Director	Director	46 600 Value: $326.7K
May 29, 2026 Buy	Common Stock A-Award	Tasse Daniel Director	Director	9 807 Value: $68.7K
May 29, 2026 Buy	Stock Options (Right to Buy) A-Award	Stump David C Director	Director	46 600 Value: $326.7K
May 29, 2026 Buy	Common Stock A-Award	Stump David C Director	Director	9 807 Value: $68.7K
May 29, 2026 Buy	Stock Options (Right to Buy) A-Award	Zachary Jennifer Director	Director	46 600 Value: $326.7K
May 29, 2026 Buy	Common Stock A-Award	Zachary Jennifer Director	Director	9 807 Value: $68.7K
May 29, 2026 Buy	Common Stock A-Award	Mills Kenneth T. Director	Director	9 807 Value: $68.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT REGENXBIO INC.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, wh...

Read Full Profile Here